International Journal of Contemporary Medicine
  • Year: 2014
  • Volume: 2
  • Issue: 1

Comparative Study of Hepatic and Renal Markers in Treatment of Kala-Azar With I.V. Amphotericin B and Oral Miltefosine

  • Author:
  • Kumar Manish1,, Ranjana 2, J R Keshari3, Sinha Kumari Indu4
  • Total Page Count: 5
  • DOI:
  • Page Number: 206 to 210

1Senior Resident, Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna, Bihar, India

2Professor, Department of Pharmacology, Patna Medical College, Patna, Bihar, India

3Assistant Professor, Department of Biochemistry, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna, Bihar, India

4Professor and Head of the Department, Department of Pharmacology, Patna Medical College, Patna, Bihar, India

*Corresponding author: Manish Kumar, Senior Resident, Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna-14, Mobile-09304093698. Email- manu072@gmail.com

Online published on 11 March, 2014.

Abstract

This study was designed to compare the hepatic and renal markers in treatment with two most commonly used drugs I.V. Amphotericin B and oral Miltefosine in diagnosed cases of KALA-AZAR. This was an ‘OBSERVATIONAL’ and ‘CROSS-SECTIONAL’ study. This study was conducted on two groups each had fifty patients. I.V. Amphotericin B and oral Miltefosine were given to group A and B respectively. Rise of serum bilirubin was not significant (p>0.05) in either group. Mean SGPT and SGOT level were more in group B than that of group A. But the rise in mean SGPT and SGOT level was not statistically significant (p>0.05). Rise in BUN was significant (p<0.01) by the 15th day in Group A patients but it did not cross the normal limit. There was not significant (p 0.05) rise in the mean serum creatinine level during treatment in patients of both groups.

Fall in serum Potassium level was significant (p<0.05) at 22nd and 30th day of treatment in group A patients while the fall was not significant (p>0.05) in group B patients. These results suggest that during treatment hepatic and renal markers were not altered significantly which warrant the withdrawal of the drug in both groups. It is highly recommended that serial monitoring of hepatic and renal markers are useful parameters in anti kala-azar therapy.

Keywords

I.V. Amphotericin B, Oral Miltefosine, Serum bilirubin, SGPT, SGOT, BUN, Serum creatinine, serum Potassium